This page provides a source hub for the medical information presented across this website.
Regulatory sources
U.S. Food and Drug Administration
FDA approval information documents the authorized uses of osimertinib, including the 2024 approval for unresectable stage III EGFR-mutated NSCLC after chemoradiation.
DailyMed
DailyMed provides the U.S. TAGRISSO labeling record, including dosage, warnings, pharmacology and dosage forms.
European Medicines Agency
The EMA Tagrisso EPAR provides European regulatory and therapeutic information.
Clinical literature
Important evidence includes:
- FLAURA — first-line advanced EGFR-mutated NSCLC.
- ADAURA — adjuvant treatment after resection.
- FLAURA2 — osimertinib plus chemotherapy.
- LAURA — treatment after chemoradiation in unresectable stage III disease.
Manufacturer sources
Brand-specific product information is also available from Beacon Pharmaceuticals, Incepta Pharmaceuticals and Everest Pharmaceuticals for Tagrix, Osicent and Osimert respectively.